October 26

Prozac Revisited: Concerns About Suicides Surface – Boston Globe

Prozac Revisited: Concerns About Suicides Surface – Boston Globe

Eli Lilly’s denial about the risk of suicide for some patients prescribed Prozac was the subject of a series of reports in the Boston Globe. The article (Sunday, June 11) revealed the irony behind the duplicity. Dr. Martin Teicher, who first wrote about the suicide link to Prozac, who was its most prominent critic, stands to grow rich from Lilly–$5 million a year– despite the company’s continued denial of his conclusions about the drugs’ link to violence & suicide.

“For perspective, imagine that car-safety crusader Ralph Nader identifies a major safety flaw in, say, the braking system used in all cars. The automakers deny that the flaw exists. Nader then invents a device that fixes the flaw and offers it to the automakers. Despite denying the problem, they pay him millions for it.

Now substitute Teicher and Lilly in those roles, and that’s what makes this a uniquely American tale about the pursuit of knowledge, the pursuit of profits, and the arranged marriages that sometimes bring them together.”


Prozac revisited
As drug gets remade, concerns about suicides surface
By Leah R. Garnett, Globe Staff, 5/7/2000

Just as the 14-year patent on Prozac is about to expire and the drug’s maker, Eli Lilly and Co., is preparing to launch a new version, a body of evidence has come to light revealing the antidepressant’s dark side.

The company’s internal documents, some dating to the mid-1980s, as well as government applications and patents, indicate that the pharmaceutical giant has known for years that its best-selling drug could cause suicidal reactions in a small but significant number of patients. The reports could become critical as Lilly seeks government approval for its new Prozac.

Among the findings:

– Internal documents show that in 1990, Lilly scientists were pressured by corporate executives to alter records on physician experiences with Prozac, changing mentions of suicide attempt to “overdose” and suicidal thoughts to “depression.”

– Three years before Prozac received approval by the US Food and Drug Administration in late 1987, the German BGA, that country’s FDA equivalent, had such serious reservations about Prozac’s safety that it refused to approve the antidepressant based on Lilly’s studies showing that previously nonsuicidal patients who took the drug had a fivefold higher rate of suicides and suicide attempts than those on older antidepressants, and a threefold higher rate than those taking placebos.

– Lilly’s own figures, in reports made available to the Globe, indicate that 1 in 100 previously nonsuicidal patients who took the drug in early clinical trials developed a severe form of anxiety and agitation called akathisia, causing them to attempt or commit suicide during the studies.

– Though Lilly has steadfastly defended the drug’s safety and downplayed studies linking Prozac to suicide, the patent for the new Prozac, R-fluoxetine, expected to be marketed by Lilly beginning in 2002, notes that the new version will not produce several existing side effects including “akathisia, suicidal thoughts, and self-mutilation,” which the patent calls “one of its more significant side effects.”

– A McLean Hospital researcher and associate professor at Harvard Medical School, Dr. Martin Teicher, whose early 1990s studies linked Prozac to akathisia and suicide, is a co-inventor of the new Prozac, which Lilly plans to market, along with Timothy J. Barberich, the CEO of Sepracor Inc., a Marlborough drug company, and James W. Young.

– A just-published book, “Prozac Backlash,” by a Cambridge psychiatrist, Dr. Joseph Glenmullen, has drawn Lilly’s ire for discussing Prozac’s link to suicide, tics, withdrawal symptoms, and other side effects of Prozac and similar antidepressants.

Lilly officials continue to defend the drug’s effectiveness, saying its track record is borne out by the fact it is still the most widely prescribed drug of its kind. In a written statement, Jeff Newton, a Lilly spokesman, said: “There is no credible evidence that establishes a causal link between Prozac and violent or suicidal behavior. There is, to the contrary, scientific evidence showing that Prozac and medicines like it actually protect against such behaviors.”

Using figures on Prozac both from Lilly and independent research, however, Dr. David Healy, an expert on the brain’s serotonin system and director of the North Wales Department of Psychological Medicine at the University of Wales, estimated that “probably 50,000 people have committed suicide on Prozac since its launch, over and above the number who would have done so if left untreated.”

Healy, meanwhile, is conducting a new study that he says is the first of its kind, giving antidepressants to healthy people to study possible links to suicide. The results are expected to be published in June.

Prozac’s success is certainly unquestioned. The introduction of the drug to the US market in the late 1980s changed the way Americans viewed their most intimate emotions and limitations. Billed as a wonder drug to combat depression by boosting levels of the brain chemical serotonin, Prozac and others like it were also said to remedy a host of human frailties from poor self-esteem and concentration to fear of rejection.

By the end of last year, more than 35 million people worldwide were using the drug, which provided Lilly with more than 25 percent of its $10 billion in 1999 revenue.

Yet the problems with Prozac were known even before it was introduced to the US market. Figures in a 1984 Lilly document indicated that akathisia, the severe agitation that can lead to suicide, occurs in at least 1 percent of patients, a level considered a “frequent” event, and as such must be disclosed in a company’s product literature and package inserts. But there is no such disclosure in Prozac’s US literature, and it is not clear whether the FDA panel charged with approving Prozac simply overlooked or did not have access to certain critical data of Lilly’s.

As a result, researchers say that most US doctors do not know to warn patients of the potentially dangerous effect which, according to published literature on the topic, can be alleviated with sedatives or by going off the drug.

German regulators, who eventually approved Prozac for use in that country, require a warning label about the risk of suicide and suggest the concurrent use of sedatives when necessary.

Akathisia is listed in Lilly’s US product literature, but as an infrequent event in Prozac users. No mention is made of its potential relationship to suicide.

A relationship, however, was found in a Globe search of US patents. The patent for the new Prozac or R-fluoxetine (US Patent no. 5,708,035), which Lilly will market after the existing patent expires in 2001, contains a wealth of information about the original Prozac. According to the patent, the new Prozac will decrease side effects of the existing Prozac such as headaches, nervousness, anxiety, and insomnia, as well as “inner restlessness (akathisia), suicidal thoughts and self-mutilation” – the same effect Lilly has contended has not occurred in any substantial way in some 200 lawsuits against it over the past decade. Most of the suits were settled out of court and the terms kept confidential.

A 1990 communique

In an electronic communique obtained by author Glenmullen dated Nov. 13, 1990, from Claude Bouchy, a Lilly employee in Germany, to three Lilly corporate executives at the company’s Indianapolis headquarters, Bouchy says he and a colleague “have problems with the directions our safety people are getting from the corporate group (Drug Epidemiology Unit) and requesting that we change the identification of events as they are reported by the physicians. . . . Our safety staff is requested to change the event term ‘suicide attempt’ [as reported by the physician] to ‘overdose.’ ”

Bouchy continued that “. . . it is requested that we change . . . ‘suicidal ideation’ to ‘depression.’ ”

And then Bouchy makes an appeal to his US Lilly colleagues: “I do not think I could explain to the BGA, to a judge, to a reporter or even to my family why we would do this especially on the sensitive issue of suicide and suicide ideation. At least not with the explanations that have been given to our staff so far.”

Lilly has also aggressively sought to discredit researchers who published data linking its product to suicide. One of its early targets was Dr. Martin Teicher, an associate professor of psychiatry at Harvard Medical School and a McLean Hospital researcher, who wrote a crucial paper on the link between suicide and Prozac in 1990; he found that 3.5 percent of patients put on Prozac either attempt or commit suicide due to severe agitation from akathisia. As a result of Lilly’s campaign, many in the psychiatric community say they believe Teicher has distanced himself from his original work. But in a rare interview with the Globe, Teicher said that he stood by his work, and that the ability of Prozac to induce suicide in a minority of patients “is a real phenomenon.”

Teicher, Barberich, and Young filed their patent for the new Prozac in August 1993, the same year Teicher published another report, this one in the journal Drug Safety titled “Antidepressant Drugs and the Emergence of Suicidal Tendencies.”

The paper was a direct challenge to data reported in the March 1991 issue of the Journal of Clinical Psychiatry by Drs. Maurizio Fava and Jerrold Rosenbaum of Massachusetts General Hospital. Their study found no significant difference in “suicidal ideation” in patients treated with fluoxetine compared to those receiving other antidepressants.

Teicher wrote in his 1993 paper that Fava and Rosenbaum’s statistics were flawed. Using Fava and Rosenbaum’s data, Teicher came to the opposite conclusion: namely, that patients on Prozac were at least three times more likely to become suicidal than those on older antidepressants.

The FDA came up with similar results even before Teicher published his 1993 data. Dr. David Graham, chief of the FDA’s Epidemiology Branch, wrote on Sept. 11, 1990, that Lilly’s data on suicide and Prozac, as well as the Fava and Rosenbaum study, were insufficient to prove that Prozac was safe. In an internal FDA memo, Graham wrote: “Because of apparent large-scale underreporting, the firm’s analysis cannot be considered as proving that fluoxetine and violent behavior are unrelated.”

“Prozac Backlash”

Now a decade later, Lilly has targeted Dr. Joseph Glenmullen, whose book “Prozac Backlash” has apparently incensed Lilly executives.

Glenmullen, a clinical instructor in psychiatry at Harvard Medical School and a clinician at the Harvard University Health Services, says he wrote the book because he was alarmed by the number of patients who were reporting severe side effects from the serotonin-boosting antidepressants including Prozac, Paxil, Zoloft, and Luvox. “The two most upsetting side effects were patients becoming suicidal on the drugs, and the development of disfiguring facial tics,” he said in an interview.

After obtaining hundreds of pages of FDA documents through the Freedom of Information Act, as well as internal Lilly memos that are part of the public record in lawsuits filed against the drug company, Glenmullen wrote that Lilly had tried to downplay side effects of Prozac for years.

Lilly alerted newspapers and TV stations to the book and began a campaign to discredit the author, saying that Harvard Medical School professors were unfamiliar with his work and didn’t recognize his name. Glenmullen, a graduate of Harvard Medical School, is one of 415 clinical instructors in medicine at Harvard.

Blast from a critic

Chief among Glenmullen’s critics is Mass. General’s Rosenbaum, a professor of psychiatry at Harvard Medical School, who, in a written statement sent to the Globe calls “Prozac Backlash” a “dishonest book” that is ” manipulative” and “mischievous.”

But Rosenbaum’s objectivity has also been questioned. Not only was his 1991 study on Prozac and suicide criticized by at least two sets of researchers as well as the FDA, documents obtained by the Globe show that Rosenbaum’s relationship to Lilly is a cozy one: he has served as a Prozac researcher and sat on a marketing advisory panel for Lilly before Prozac was launched.

When asked in an interview why he was speaking out against Glenmullen’s book, Rosenbaum said that the suicide controversy was “old news” and that the book presents the information as new research. He noted that akathisia is “pretty rare” and that “it doesn’t occur more than in people given a placebo.”

But because there is no official reporting system for drug side effects, no one knows how common drug side effects are, said Larry Sasich, a research analyst at Public Citizen in Washington, D.C.

“There is no active surveillance system to look at adverse events,” he said. “Unless something very unfortunate happens and a large number of people are harmed in a unique way, no one is going to look at it; nobody ever puts two and two together.”

Sepracor’s patent

On April 12, the Federal Trade Commission opened the way for Lilly to market Teicher’s, Barberich’s, and Young’s new Prozac, for which Sepracor holds the patent. The new Prozac, R-fluoxetine, is a modified form of an ingredient found in Prozac, which, according to Sepracor, not only has fewer side effects but more potential uses and benefits than the original.

In making the decision, the FTC rejected arguments from its lawyers and the generic drug industry that the agreement unfairly limits generic Prozac competition.

According to a Sepracor press release dated April 13, the company will receive an upfront payment and license fee of $20 million from Lilly and an additional $70 million based on the progression of the drug. Sepracor will receive royalties, and in exchange, Lilly will get the exclusive world rights to R-fluoxetine for all indications and uses. Lilly will be responsible for the development of the drug, regulatory submissions, product manufacturing, marketing and sales, according to the release.

Glenmullen wonders whether the new Prozac will, in fact, be little more than an effort to prolong the life of a product with a soon-to-expire patent.

Although it is touted as having fewer side effects, no one knows what effects may surface once large numbers of people begin taking it for months or years. In the epilogue to his book, he simply says: “Like any new drug, it too will be an ongoing experiment.”


This story ran on page A01 of the Boston Globe on 5/7/2000. Copyright 2000 Globe Newspaper Company.

Bouchy memo Nov 14,1990

PROZAC – New directions
Science, money drive a makeover
By Mitchell Zuckoff, Globe Staff, 6/11/2000

This is a story about a drug that changed the world, the bravery of rats, the evolution of a psychiatrist, the Jekyll and Hyde nature of man-made chemicals, the Church of Scientology, and the impulses that lead some people to kill.

It is also about money. Lots of money.


image (omitted)

In 1848, Louis Pasteur discovered that some molecules can exist in mirror forms – the same chemical composition can build shapes that curve one way or another, said to be left – or right-handed. Natural molecules come in only one shape, but the procedures for creating manmade molecules create both left- and right-handed forms at the same time. Sold as the antidepressant drug Prozac, fluoxetine include the two shapes, called isomers, pictured below. Because the different isomers are difficult to separate, the FDA allows drug companies to include both in medicines, as long as the less-functional isomer is not harmful. Isolating R-fluoxetine could yield a more effective drug with fewer side effects.


The drug is Prozac, and its resume is lore: Introduced by Eli Lilly and Co. in 1988 as the first notable new antidepressant in two decades, it lifted the spirits of millions and became shorthand for the search for answers in convenient pill form.

Yet its triumphs have been clouded by persistent accusations, denied by Lilly, that a small but significant percentage of Prozac users suffer a side effect that runs counter to the drug’s intent: intense agitation that in rare cases explodes into violence, suicide, or both.

Now, as the familiar green-and-white pill approaches the humbling status of a generic drug in 2004, along comes a new drug derived from Prozac – ostensibly without the dangerous side effects – that is designed to take Prozac’s place in the medicine cabinet and on Lilly’s billion-dollar balance sheet.

And along with that new drug comes a most unexpected helpmate for Lilly: a Harvard psychiatrist named Martin H. Teicher, who in the space of a decade has taken an extraordinary journey.

Once Prozac’s most prominent critic – author of the first scientific paper to wave the red flag of suicide and violence Teicher is now enjoying what he calls a ”wonderfully ironic” role as co-inventor of the Prozac replacement drug.

With a high-flying Massachusetts drug firm acting as middleman, Teicher stands to grow rich from Lilly, despite its continued rejection of his conclusions about suicide. If the new Prozac clears ongoing trials and proves even moderately successful compared to its predecessor, Teicher could supplement his associate professor’s salary by more than $5 million a year.

At the same time, Teicher’s decade-old observations about Prozac’s dangers have resurfaced in a very awkward way for Lilly. The drug patent obtained by Teicher and his co-inventors says the new Prozac is free from the suicide side effect, and last week that claim became the basis for a federal fraud lawsuit against Lilly. The lawsuit essentially accuses Lilly of denying any Prozac-suicide link on the one hand, yet buying an exclusive license for a patent that says otherwise.

For perspective, imagine that car-safety crusader Ralph Nader identifies a major safety flaw in, say, the braking system used in all cars. The automakers deny that the flaw exists. Nader then invents a device that fixes the flaw and offers it to the automakers. Despite denying the problem, they pay him millions for it.

Now substitute Teicher and Lilly in those roles, and that’s what makes this a uniquely American tale about the pursuit of knowledge, the pursuit of profits, and the arranged marriages that sometimes bring them together.

The psychiatrist’s den

Teicher’s office at the Harvard-affiliated McLean Hospital in Belmont has all the trappings of a psychiatrist’s den. There is the leather couch, the bursting bookcase, and the wall of diplomas – PhD from Johns Hopkins in 1977, MD four years later from Yale University. A clock chimes to mark the passing hours.

There are personal touches, too: a jar on a shelf jokingly labeled ”Ashes of former students”; and a quote on the wall from Voltaire, ”No problem can withstand the assault of sustained thinking.” A plaque commemorating one of Teicher’s two Prozac-related patents hangs over his desk. There are two paintings, one of a sad clown and the other of a frightened child. They were painted by the psychiatrist’s mother.

Teicher, 49, is a suit-and-tie native of New York’s endless suburb, Long Island. Divorced, he lives in Waltham; after the divorce, his ex-wife took a job as a cancer researcher for none other than Lilly, which Teicher calls ”an odd happenstance of coincidence.”

He does not seek publicity; would-be interviewers have to run a gantlet of McLean public relations officials. Once he agrees to talk, however, Teicher is gracious, if seemingly detached from the subject that could make him rich and, in certain circles, famous.

”This is just one small part of what I do, a minor offshoot,” Teicher says quietly, preferring to talk about his recent work on attention-deficit and hyperactivity disorders.

In fact, a McLean-supplied biographical sketch that lists 58 of his publications between 1976 and 2000 does not include the scientific paper that set him on the Prozac path, and for which he is arguably most widely known: ”Emergence of Intense Suicidal Preoccupation During Fluoxetine (Prozac) Treatment.”

Its absence notwithstanding, there is no denying the paper’s impact.

Just four pages, it was written by Teicher, a nurse named Carol Glod (who has since earned a doctorate), and fellow Harvard psychiatrist Jonathan O. Cole. It was published in February 1990 in the prestigious American Journal of Psychiatry.

In the dry language of academia, the paper describes six depressed patients, ages 19 to 62, five of whom had considered killing themselves in the past but none of whom had recent suicidal thoughts.

The authors detail how all six became powerfully suicidal – stricken by a ”state more intense, obsessive, and violent than anything they previously had experienced” – within weeks of beginning Prozac treatment, and remained so for anywhere from three days to three months after discontinuing the drug. One put a loaded gun to her head, and another had to be restrained to prevent self-mutilation. None committed suicide.

With the imprimatur of Harvard psychiatry, the paper was received by many as proof of the anecdotal and media reports that flourished in the years after Prozac’s introduction.

Among the most dramatic was the story of Joseph Wesbecker, a deeply disturbed Kentucky printing-press operator who in 1989 walked into his workplace and killed eight people, then himself. Wesbecker had begun taking Prozac weeks earlier, and its effects had alarmed his psychiatrist, who unsuccessfully urged Wesbecker to discontinue the drug just days before the carnage.

Prozac doubters seized on Teicher’s paper to press the US Food and Drug Administration to ban, or at least investigate, Prozac and similar antidepressants.

That is where the Church of Scientology fits in. The most ardent Prozac critics were members of a group affiliated with Scientology, which was founded by science-fiction writer L. Ron Hubbard, in part based on his hatred of psychiatry.

The group trumpeted Teicher’s paper and blanketed the media with claims that Prozac was a ”killer drug.” In one press release the group stated that ”the numbers of persons who have been driven or are being driven suicidal or homicidal by Prozac is astronomical.” It was one of many subtle and not-so-subtle distortions of Teicher’s paper.

Teicher and his coauthors had written that the dangerous side effect was observed in 3.5 percent of all their patients, and the Scientologists extrapolated that figure to the entire population of Prozac users. It was a leap Teicher says had no basis in science and left him deeply frustrated.

Teicher says his contact with the Scientologists was limited to one phone call in which he complained they were distorting his data. Yet, he says, he suffered ”guilt by association,” despite the fact that he always believed Prozac was a valuable addition to the psychiatrist’s toolbox, ”a breakthrough” drug that simply needed to be monitored closely for troubling side effects.

But, for the most part, all anyone heard was that Teicher had linked Prozac to suicide, and the Scientologists were citing him as their most potent ally.

The psychiatric community circled the wagons to oppose the Scientologists’ attacks on Prozac and the entire profession, sweeping up Teicher in what he called a ”strange, surreal” process. Lilly fought back as well, offering studies and scientists to challenge Teicher’s work and sending out press releases of their own to counter the criticism.

A climax of sorts was reached in 1991, when the FDA dismissed any link between suicide and Prozac or similar antidepressants.

A nine-member panel of experts voted unanimously that there was ”no credible evidence” of any association, and split 6-3 against requiring a stronger warning label.

In the aftermath, critics disparaged the panel – ”a kangaroo court,” in the words of one lawyer who has pending lawsuits against Lilly – as riven by conflicts of interest and armed with flawed data from the company’s clinical studies. Lilly also came under fire.

”Lilly’s efforts to discredit clinicians, scientists, and journalists trying to foster greater discussions, research, and awareness of this side effect is one of the most disgraceful chapters in American corporate history,” said Harvard psychiatrist Joseph Glenmullen, author of the new book ”Prozac Backlash,” which focuses in part on tendency toward suicide.

Still, the FDA’s finding has been the cornerstone of Lilly’s defense of Prozac in public and the courts.

Lilly officials declined several requests for interviews, but in a written statement the company restated the 1991 FDA decision:

”There is no scientific evidence that establishes a link between Prozac and violent or suicidal behavior.”

Today, Teicher looks back on the early 1990s with what seems like preternatural equanimity: ”It was a good life lesson. I basically did fine.”

Asked to define the lesson, he says: ”What I learned from all this is I cared much less what people thought. … There are always going to be colleagues who disagree with me about this. A definitive study hasn’t been done. Maybe 20 years from now there will be a clear answer, but maybe not.”

Partners looking for ‘cure’

What his critics did not know was that Teicher, since early 1992, had been working on what might be called a ”cure” for the problems he saw in Prozac.

By all accounts, that turn of events began one morning when a bear of a man named Timothy J. Barberich was reading The Wall Street Journal. He came across a story about the Prozac controversy that mentioned Teicher’s work.

Barberich was not just any reader, though. He had parlayed his undergraduate chemistry degree into founder, chairman, and chief executive of an upstart drug company called Sepracor Inc., in Marlborough, half an hour west of Teicher’s office.

Barberich and one of his top scientists, James W. Young, decided to call Teicher to talk about a chemical process Sepracor had developed to reformulate existing drugs by removing unwanted side effects. By the early 1990s, the company had targeted 40 or so already-approved drugs – including Prozac – that it hoped to improve, patent, and then market on its own or in partnership with the old drugs’ owner.

Teicher, as it turns out, had been studying the science of that process in his laboratory, feeding different chemical substances to rats and sending them into a maze. In early 1992, Teicher and Sepracor struck a deal under which the company would fund about $150,000 of research in his lab.

To understand what happened next requires a painless chemistry lesson, first taught in the 1800s by Louis Pasteur. Pasteur discovered that most man-made chemical compounds – prescription drugs, for instance – exist at a microscopic level as twins, called isomers. Although the twins are chemically identical, each one is not the mirror image of the other. In some drugs, only one of the twins provides the benefits, fitting into chemical receptors in the body to flip switches on or off to fight illness. The other twin does not fit the same receptors, so it is free to wander through the body. Sometimes it goes looking for trouble. That is, causing side effects.

The most dramatic example was the 1960s drug thalidomide, one of whose twins was the good Dr. Jekyll, effectively decreasing morning sickness in pregnant women. The other was the evil Mr. Hyde, a chemical monster that caused horrible birth defects.

Until the last 20 years or so, it was difficult to separate the twins- and sometimes, both twins have problems of their own – so government regulators allowed drugmakers to sell medicines including both, as long as the side effects were not terrible.

That was Lilly’s argument for Prozac, which allows brain cells to bathe more freely in a chemical called serotonin, which affects mood and emotion. To this day, despite millions of prescriptions for the drug, scientists are not certain precisely how Prozac works, but it is generally believed that the added serotonin in a brain on Prozac lessens depression.

Lilly acknowledges that the current formula also can cause side effects including non-life-threatening ailments such as headaches, anxiety, tremors, and sexual dysfunction. But not suicidal tendencies.

Teicher and Sepracor set out to find a way to keep the good parts of Prozac, or improve it, while eliminating the bad. Within six months of starting his work, Teicher and Sepracor officials say, he recognized which of the Prozac twins was the one most worth keeping. Teicher noticed that when he gave his rats the part of Prozac that would be considered the ”good” twin – known chemically as R-fluoxetine – the rodents bravely explored the more dangerous, exposed parts of the maze, spending less time anxiously scurrying to the enclosed, protected areas.

It took a lot more work, lots more rats, and five more years to get a patent, during which both Teicher and Sepracor experienced bumps in the road. Teicher weathered an embarrassing state medical board investigation into allegations, eventually dismissed, of sexual misconduct with a patient. Sepracor, meanwhile, was frustrating stockholders with yearly losses. Eventually, though, Teicher and the two Sepracor officials, Barberich and Young, succeeded in patenting their discovery, receiving one in 1997 and the second in 1998.

The patents tout their drug’s effectiveness as an antidepressant and appetite suppressant, an anxiety reliever, and a potential treatment for migraine headaches, chronic pain, and obsessive-compulsive disorders. Its residual effects leave the body sooner than the existing Prozac, the patent says, allowing doctors to try other drugs more quickly if it proves ineffective.

Lilly has no problem with any of that. But then comes the patent language that has caused the current uproar: ”The adverse affects (sic) which are decreased by administering the [new version of Prozac] include but are not limited to headaches, nervousness, anxiety, insomnia, inner restlessness (akathisia), suicidal thoughts and self-mutilation.”

And so, with one swing of a patent examiner’s approval stamp, Lilly’s decade-long denials about suicidality ran headlong into the claims of a promising new drug that Lilly was eager to buy.

Difficulty protecting Lilly Teicher refers questions about the patent to Sepracor, and Barberich finds himself in the awkward position of defending the new Prozac without offending his powerful partner, Lilly.

First, Barberich downplays the issue: ”I don’t want to get my patent disallowed, but it’s not as if you have any evidence for what you’re claiming in the broadest sense. … There’s no court of truth that these patents go through. I believe that they, Lilly, are correct.”

Then, he hedges: ”Marty Teicher may be right, Eli Lilly may be right, and the FDA may be right, and we still wouldn’t have any idea whether [the new drug] eliminates a problem that we’re not sure exists.”

Although Lilly officials would not discuss the patent, their statement sought to put distance between Lilly and the damaging patent language: ”Lilly had no input nor provided content for the patent application. Not all the ‘side effects’ listed in the patent are scientifically demonstrated facts. … Teicher’s article was a series of anecdotal reports, and his suggestions of a ‘possibility’ of a causal relationship have been refuted by multiple … studies that have demonstrated no increased risk of suicide associated with Prozac use.”

Barberich also said Lilly had no role in the patent. He said the Indianapolis-based drugmaker opened talks with Sepracor only after the patent was certain to be approved.

He also said there were no discussions with Lilly about the suicide issue when Lilly purchased exclusive rights to the patent in late 1998. The deal gives Sepracor $20 million up front – due to be paid by the end of this month – plus another $70 million if the drug gets FDA approval, as anticipated within the next two years.

If that approval comes, the real money for Sepracor, Teicher, and McLean Hospital could start rolling in as early as 2002. ”It’s likely it’s going to be a big drug. It’s just a question of how big,” Barberich said.

Under the terms of the deal with Lilly, Sepracor gets about 10 percent of sales. McLean gets 10 percent of that, of which the hospital gets half, Teicher personally gets one-quarter and his laboratory gets one-quarter.

Prozac revenues for Lilly were $2.6 billion last year. If the new Prozac becomes a $2 billion-a-year drug, Sepracor would get $200 million a year, of which McLean gets $10 million, and Teicher and his lab each would receive $5 million.

Back in his office, Teicher acknowledges that he finds himself thinking about the money sometimes. He said a need for money prompted him to stop seeing patients two years ago, so he could focus on ”entrepreneurial” activities to fund his son’s college education.

He also thinks about the potential conflict involved in prescribing and lecturing about a drug in which he has a large financial stake, but he expects to handle that by simply disclosing his interest.

Teicher says he spends almost no time thinking about a patent on his wall that says he was right all along, and even less time thinking about vindication.

”I’m not sure vindication will ever come,” he says. ”I’m not sureI need it or want it.”

This story ran on page A1 of the Boston Globe on 6/11/2000.

© Copyright 2000 Globe Newspaper Company.

FAIR USE NOTICE: This may contain copyrighted (© ) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available for educational purposes, to advance understanding of human rights, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a ‘fair use’ of any such copyrighted material as provided for in Title 17 U.S.C. section 107 of the US Copyright Law. This material is distributed without profit.

Subscribe To Our Newsletter!

Sign up and be the first to find out the latest news and articles about what's going on in the medical field.

You may also like

November 21, 2023

Vera Sharav is joining Christine Anderson as special guest for the Make It Your Business event in

Read More
Vera Sharav Joins Christine Anderson for Make It Your Business – Dec 4, 2023 in New Jersey

November 21, 2023

Vera Sharav is premiering the movie Never Again is Now Global in New York City, December 1.

Read More
Never Again is Now Global – Premiere Screening – Dec 1, 2023 in New York City